MADISON, N.J., March 21, 2011 /PRNewswire/ — Quest Diagnostics
Incorporated (the “Company”) (NYSE: DGX), the world’s leading
provider of diagnostic testing, information and services, announced
today that it intends to offer $1,250,000,000 in aggregate
principal amount of four series of senior notes in a public
offering made under a shelf registration statement filed with the
Securities and Exchange Commission, subject to market and other
conditions. The notes will be fully and unconditionally
guaranteed on a senior, unsecured basis by certain of the Company’s
domestic, wholly owned subsidiaries.
The issuance of the notes will be subject to customary closing
conditions. The Company intends to use the net proceeds from
the offering to fund the purchase price and related transaction
costs of its acquisition of Athena Diagnostics, Inc. and to repay
outstanding indebtedness under its senior unsecured revolving
credit facility and secured receivables credit facility.
Morgan Stanley & Co. Incorporated, Goldman, Sachs &
Co., RBS Securities Inc., J.P. Morgan Securities LLC and Wells
Fargo Securities, LLC will be joint bookrunning managers for the
debt offering. When available, copies of the preliminary
prospectus supplement and the accompanying base prospectus for the
offering can be obtained from Morgan Stanley & Co. Incorporated
tollfree at (866) 7181649, Goldman, Sachs & Co. tollfree
at (866) 471-2526, RBS Securities Inc. tollfree at
(866) 8842071, J.P. Morgan Securities LLC at (212) 834-4533
and Wells Fargo Securities, LLC toll-free at (800) 326-5897.
This press release shall not constitute an offer to sell or a
solicitation of an offer to purchase any of these securities and
shall not constitute an offer, solicitation or sale in any state or
jurisdiction in which such an offer, solicitation or sale would be
unlawful. This offering may be made only by means of a
prospectus supplement and acc
‘/>”/>
